IIBBA   05544
INSTITUTO DE INVESTIGACIONES BIOQUIMICAS DE BUENOS AIRES
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
Oncoprotein based immunotherapy for HPV-linked cervical cancer
Autor/es:
CERUTTI, M.L
Lugar:
Ciudad de buenos Aires
Reunión:
Conferencia; FAIC2010. First French-Argentine Immunology Congress; 2010
Institución organizadora:
Sociedad Argentina de Inmunología
Resumen:
High-risk human papillomaviruses (HPV) are the main etiological agent of cervical cancer, the leading cause of cancer death among women in low-income countries.  Furthermore, they are also highly associated with the development of others anogenital and oropharyngeal carcinomas.  Commercially available prophylactic HPV vaccines were shown to be ineffective on pre-existing neoplastic processes, thus having no immediate impact on the actual incidence of HPV-related cancers.  HPV E7 and E6 early oncoproteins represent ideals targets for immunotherapeutic intervention due to their key role in cellular transformation and constitutive expression in HPV-associated tumors.  Recently, we have developed a recombinant E7-based vaccine, exhibiting strong immunotherapeutic properties in a well established HPV-16 tumour model.  Vaccination of female mice with low doses of the recombinant HPV-16 E7vaccine totally prevented tumour outgrowth, even after a 3 months re-challenge.  Therapeutic treatment of tumour-bearing mice with the vaccine-type molecule also shows a remarkable activity, completely reverting the tumor growth.  Preliminary in vitro experiments demonstrate that the in vivo therapeutic effect of our E7-based vaccine is due to the induction of a long lasting CD8+ T-cell response.  These proof-of-principle experiments demonstrate the potential applicability of our vaccine candidate to the treatment of HPV-related neoplastic lesions.